Previously, DMC asked Merck to terminate patient recruitment as the study failed to meet the formal futility criteria.
The decision was based on the data which showed overall mortality and multi-organ dysfunction that occurred with greater frequency in vaccine recipients, compared with placebo recipients.
Further, V710 did not show a statistically significant clinical benefit compared with a placebo.